These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1518 related items for PubMed ID: 25366984

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ.
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
    Irwin N, Hunter K, Montgomery IA, Flatt PR.
    Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
    [Abstract] [Full Text] [Related]

  • 6. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL.
    BMJ; 2012 Jan 10; 344():d7771. PubMed ID: 22236411
    [Abstract] [Full Text] [Related]

  • 7. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW, Torekov SS, Holst JJ.
    Expert Opin Pharmacother; 2014 Dec 10; 15(17):2487-500. PubMed ID: 25260877
    [Abstract] [Full Text] [Related]

  • 8. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT, Kieffer TJ.
    Minerva Endocrinol; 2002 Jun 10; 27(2):79-93. PubMed ID: 11961501
    [Abstract] [Full Text] [Related]

  • 9. Exenatide: a novel approach for treatment of type 2 diabetes.
    Mikhail N.
    South Med J; 2006 Nov 10; 99(11):1271-9. PubMed ID: 17195423
    [Abstract] [Full Text] [Related]

  • 10. Exenatide and weight loss.
    Bradley DP, Kulstad R, Schoeller DA.
    Nutrition; 2010 Mar 10; 26(3):243-9. PubMed ID: 20152707
    [Abstract] [Full Text] [Related]

  • 11. [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
    Scheen AJ.
    Rev Med Liege; 2007 Apr 10; 62(4):217-21. PubMed ID: 17566392
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
    Albèr A, Brønden A, Knop FK.
    Diabetes Obes Metab; 2017 Jul 10; 19(7):915-925. PubMed ID: 28211611
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H, Erdmann E.
    Dtsch Med Wochenschr; 2007 Mar 16; 132(11):571-4. PubMed ID: 17342635
    [Abstract] [Full Text] [Related]

  • 18. Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
    Sakai T, Kusakabe T, Ebihara K, Aotani D, Yamamoto-Kataoka S, Zhao M, Gumbilai VM, Ebihara C, Aizawa-Abe M, Yamamoto Y, Noguchi M, Fujikura J, Hosoda K, Inagaki N, Nakao K.
    Am J Physiol Endocrinol Metab; 2014 Oct 15; 307(8):E712-9. PubMed ID: 25159327
    [Abstract] [Full Text] [Related]

  • 19. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B, Bonnard C, Renard E.
    Diabetes Metab; 2011 Dec 15; 37(6):477-88. PubMed ID: 21871831
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.